PubMed Health⌕ Search

Biomedical subjects

M Wilen

Publications and source records attributed to M Wilen.

6 recordsLinked to original sources

Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure.

The cause of exercise intolerance in congestive heart failure is unclear. Hemodynamic and ventilatory responses were measured during symptomatic maximal upright bicycle exercise in 28 patients with chronic severe left ventricular failure who achieved a maximal oxygen uptake of only 12 +/- 4 ml/min/kg (+/- standard deviation). All patients reached anaerobic metabolism as the respiratory exchange ratio rose and arterial pH fell significantly. Pulmonary capillary wedge pressure increased from 20 +/- 10 mm Hg at rest to 38 +/- 9 mm Hg at peak exercise and cardiac index increased from 2.51 +/- 0.73 to 4.54 +/- 1.65 liters/min/m2 (both p less than 0.001). Systemic vascular resistance decreased, but pulmonary vascular resistance did not change during exercise. Despite the marked pulmonary venous hypertension at peak exercise, blood gases were unchanged (PaO2, 96 +/- 15 mm Hg; PaCO2, 35 +/- 7 mm Hg). Systemic arterial oxygen content increased from 16 +/- 2 to 17 +/- 2 vol% (p less than 0.01). Changes in pulmonary capillary wedge pressure did not correlate with changes in arterial oxygen content. Results were similar whether patients were limited by dyspnea or fatigue. Thus, exercise intolerance in patients with severe left ventricular failure is associated with marked elevation of pulmonary capillary wedge pressure and anaerobic metabolism without hypoxemia or altered carbon dioxide tension. These findings suggest that exercise ability in congestive heart failure is more dependent on cardiac output than on ventilatory consequences of pulmonary congestion.

Adult↗

Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure.

Enalapril (MK-421) is a new oral angiotensin-converting enzyme inhibitor which was administered to eight patients with chronic congestive heart failure. Four hours after enalapril administration (10 to 20 mg), mean arterial pressure fell from 95.6 +/- 11.4 (SD) to 84.8 +/- 17.6 mm Hg (p less than 0.05), systemic vascular resistance fell from 18.5 +/- 3.0 to 15.8 +/- 4.1 units (p less than 0.02), while pulmonary artery wedge pressure changed insignificantly from 17.5 +/- 9.2 to 14.5 +/- 10.2 mm Hg and cardiac index rose insignificantly from 2.63 +/- 0.46 to 2.82 +/- 0.75 L/min/m2. These hemodynamic effects persisted during one month of enalapril administration. Baseline plasma renin activity of 0.76 +/- 1.07 ng/ml/hr rose to 3.23 +/- 2.87 ng/ml/hr (p less than 0.05) after one month of enalapril administration. During the month of enalapril administration, maximal exercise duration rose from 465.1 +/- 233.0 to 572.3 +/- 233.7 seconds (p less than 0.05), and maximal oxygen uptake increased from 12.3 +/- 2.7 to 16 +/- 11.2 ml/min/kg (p less than 0.05). No major side effect occurred. These sustained effects may be clinically beneficial, and enalapril deserves further evaluation in the long-term treatment of patients with chronic congestive heart failure.

Angiotensin-Converting Enzyme Inhibitors↗

Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs.

Enalapril (MK-421) is a new angiotensin converting enzyme inhibitor which effectively lowers elevated blood pressure and might also be useful in heart failure. Enalapril was infused into six awake dogs 2 hours after left circumflex coronary artery embolization (acute failure group) and into six other awake dogs two to six months after coronary embolization (chronic failure group). In the acute failure group 2 hours after embolization, increased left ventricular end-diastolic pressure and reduced cardiac output remained unchanged during enalapril infusion. In the chronic failure group, increased left ventricular end-diastolic pressure also remained unchanged during enalapril infusion, but cardiac output, which had fallen to 131.8 +/- 11.9 (S.D.) from 165.8 +/- 17.9 ml/min/kg (P less than 0.01) by two to six months in this group rose during enalapril infusion to 154.5 +/- 27.7 ml/min/kg (P less than 0.05). Heart rate and blood pressure were not changed during enalapril in either group, but stroke volume rose (26.0 +/- 5.9 to 29.2 +/- 6.9 ml, P less than 0.01) and systemic vascular resistance fell (58.5 +/- 10.3 to 39.3 +/- 4.3 units, P less than 0.01) during enalapril only in the chronic failure group. Plasma renin activity after embolization was slightly but not significantly higher in the acute failure group. Thus, enalapril appears to be an arterial vasodilator in dogs with chronic but not acute left ventricular failure.

Angiotensin-Converting Enzyme Inhibitors↗